| Not Yet Recruiting | Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT NCT07254793 | University of Arizona | Phase 1 |
| Not Yet Recruiting | Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients NCT07269470 | M.D. Anderson Cancer Center | Phase 2 |
| Not Yet Recruiting | Impact of Tyrosine Kinase Inhibitors on Glucose Level and Lipid Metabolism in Chronic Myeloid Leukemia Patient NCT07413263 | Assiut University | — |
| Enrolling By Invitation | Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chroni NCT07383298 | Qian Jiang | — |
| Recruiting | Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagno NCT06817720 | M.D. Anderson Cancer Center | Phase 2 |
| Not Yet Recruiting | Expression Pattern and Possible Clinical Significance of CD81 In Myeloid Leukemia NCT07146542 | Assiut University | — |
| Recruiting | A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias NCT06994676 | Crossbow Therapeutics, Inc. | Phase 1 |
| Completed | TGRX-678 Pharmacokinetic Mass Balance NCT06986772 | Shenzhen TargetRx Co., Ltd. | Phase 1 |
| Recruiting | PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML NCT06409936 | Gruppo Italiano Malattie EMatologiche dell'Adulto | Phase 2 |
| Recruiting | Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Mal NCT07238712 | St. Petersburg State Pavlov Medical University | Phase 2 |
| Completed | TGRX-678 Phase I Oral Pharmacokinetic Study NCT06697899 | Shenzhen TargetRx Co., Ltd. | Phase 1 |
| Recruiting | Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral NCT06398457 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | EARLY_Phase 1 |
| Recruiting | TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients NCT06453902 | Shenzhen TargetRx Co., Ltd. | Phase 2 |
| Recruiting | The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients Wit NCT06390306 | Peking University People's Hospital | — |
| Recruiting | Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen NCT06532084 | St. Petersburg State Pavlov Medical University | Phase 2 |
| Recruiting | Vitamin A and D Supplementation in Allogeneic HCT NCT06508099 | St. Petersburg State Pavlov Medical University | Phase 2 |
| Recruiting | Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignan NCT05800210 | University of Florida | Phase 2 |
| Recruiting | Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial NCT06355583 | Imperial College London | Phase 2 |
| Recruiting | A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in NCT06163430 | Terns, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- C NCT06092879 | Novartis Pharmaceuticals | — |
| Recruiting | Study of Olverembatinib (HQP1351) in Patients With CP-CML NCT06423911 | Ascentage Pharma Group Inc. | Phase 3 |
| Recruiting | Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leu NCT06236724 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia NCT06229860 | University of California, Irvine | — |
| Active Not Recruiting | HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantati NCT06001385 | Center for International Blood and Marrow Transplant Research | Phase 2 |
| Active Not Recruiting | Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion NCT05236764 | Baylor College of Medicine | N/A |
| Recruiting | Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune NCT05753384 | Poitiers University Hospital | Phase 3 |
| Active Not Recruiting | Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML NCT05413915 | Sarit Assouline | Phase 3 |
| Active Not Recruiting | Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR) NCT05768711 | Groupe Francophone des Myelodysplasies | Phase 2 |
| Withdrawn | A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as NCT05201183 | Naoyuki G. Saito, M.D., Ph.D. | Phase 1 / Phase 2 |
| Active Not Recruiting | Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant NCT04167683 | Rigshospitalet, Denmark | — |
| Active Not Recruiting | Venetoclax After TKI to Target Persisting Stem Cells in CML NCT05701215 | Thomas Ernst, PD Dr. med. | Phase 2 |
| Recruiting | Asciminib RMP Study NCT05943522 | Novartis Pharmaceuticals | — |
| Completed | Real-World Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia in Earlier Lines of Th NCT06692803 | Novartis Pharmaceuticals | — |
| Active Not Recruiting | The Analysis of Fatigue on Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia NCT06233890 | Imperial College Healthcare NHS Trust | — |
| Recruiting | CML Pediatric ITK Response According to Molecular Identification at Diagnosis NCT05605379 | University Hospital, Bordeaux | — |
| Completed | Real-World Usage of Asciminib Among Patients With Chronic Myeloid Leukemia in Chronic Phase in the United Stat NCT06148493 | Novartis Pharmaceuticals | — |
| Suspended | Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbet NCT05400122 | David Wald | Phase 1 |
| Recruiting | Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection NCT05334069 | Alliance for Clinical Trials in Oncology | — |
| Not Yet Recruiting | Treatment Free Remission (TFR) in CML Patients （CML-CP）Study NCT05440747 | Guangdong Provincial People's Hospital | — |
| Recruiting | Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Pha NCT05282108 | Hikma Pharmaceuticals LLC | — |
| Recruiting | A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies NCT05362773 | MacroGenics | Phase 1 |
| Completed | Special Drug Use-results Surveillance of Scemblix Tablets NCT05421091 | Novartis Pharmaceuticals | — |
| Completed | MargheRITA (Remote Intelligence for Therapeutic Adherence) NCT05260203 | Advice Pharma Group srl | N/A |
| Recruiting | A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia NCT05304377 | Enliven Therapeutics | Phase 1 |
| Completed | Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Pat NCT05433532 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Completed | Off-the-shelf NK Cells + SCT for Myeloid Malignancies NCT05115630 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies NCT05130138 | Centre Hospitalier Universitaire de Saint Etienne | N/A |
| Recruiting | Italian Treatment Free Remission Registry NCT04769947 | University of Turin, Italy | — |
| Unknown | Dasatinib Down-regulates the Expression of PD-1 and Enhances Killing pH + Leukemia Stem Cells NCT04991532 | Nanfang Hospital, Southern Medical University | — |
| Recruiting | KRT-232 and TKI Study in Chronic Myeloid Leukemia NCT04835584 | Kartos Therapeutics, Inc. | Phase 1 / Phase 2 |
| Completed | The Registry of Oncology Outcomes Associated With Testing and Treatment NCT04028479 | Taproot Health | — |
| Completed | French Study to Highlight the Unmet Treatment Needs of 3L+ CP-CML and With T315I-mutated CML Patients NCT05619978 | Novartis Pharmaceuticals | — |
| Active Not Recruiting | Innate T Cells and TKI Discontinuation NCT04645706 | Poitiers University Hospital | — |
| Unknown | TIGIT in Patients With Chronic Myeloid Leukemia NCT04818619 | Assiut University | — |
| Terminated | Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer Medications NCT04595851 | University of Michigan Rogel Cancer Center | N/A |
| Completed | Study Conducted Among Patients With CML NCT05476562 | Novartis Pharmaceuticals | — |
| Unknown | Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence NCT04663100 | University of Tennessee | N/A |
| Completed | Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies NCT04943757 | St. Petersburg State Pavlov Medical University | Phase 2 |
| Recruiting | Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Populatio NCT04626024 | Baylor College of Medicine | Phase 2 |
| Completed | Clinical Outcomes of 3L+ Therapies Among Patients With Chronic Myeloid Leukemia and Those With T315I Mutation NCT05611216 | Novartis Pharmaceuticals | — |
| Completed | Retro-prospective Observational Study on Risk of Progression in CP-CML Patients Eligible for TKI Discontinuati NCT04621851 | University of Milano Bicocca | — |
| Completed | A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors NCT04605211 | University of California, San Francisco | N/A |
| Active Not Recruiting | The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I NCT04233346 | Otsuka Beijing Research Institute | Phase 2 |
| Withdrawn | HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation NCT04464889 | Medigene AG | Phase 1 |
| Completed | CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML NCT04151706 | Robert Lowsky | Phase 2 |
| Recruiting | Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-tran NCT03533816 | University of Kansas Medical Center | Phase 1 |
| Unknown | A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) NCT04578847 | National Research Center for Hematology, Russia | Phase 2 |
| Recruiting | Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL NCT04260022 | Ascentage Pharma Group Inc. | Phase 1 |
| Unknown | Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP NCT04155411 | Shenzhen Second People's Hospital | Phase 4 |
| Active Not Recruiting | Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancie NCT04013685 | Orca Biosystems, Inc. | Phase 1 |
| Active Not Recruiting | Frontline Asciminib Combination in Chronic Phase CML NCT03906292 | University of Jena | Phase 2 |
| Unknown | Leukemic Stem Cell Detection for Chronic Myeloid Leukemia Patients With Major Molecular Response NCT04104035 | Ankara University | — |
| Completed | Effects of a Digital Patient Platform (CMyLife) for Patients With Chronic Myeloid Leukemia (CML) on Informatio NCT04595955 | Radboud University Medical Center | N/A |
| Completed | Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients NCT03885830 | UNC Lineberger Comprehensive Cancer Center | — |
| Unknown | Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid NCT04043676 | Fundación Teófilo Hernando, Spain | Phase 2 |
| Completed | Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients: Observatory Trial Studying the Biological Facto NCT03996096 | University Hospital, Caen | — |
| Completed | Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis NCT03831776 | St. Olavs Hospital | Phase 2 |
| Completed | A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia NCT03874858 | Novartis Pharmaceuticals | Phase 2 |
| Unknown | Safety and Feasibility of the Use of Natural Killer Cells in Patients With Chronic Myeloid Leukemia NCT03348033 | Hospital de Clinicas de Porto Alegre | Phase 1 / Phase 2 |
| Completed | Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic NCT03455517 | Gruppo Italiano Malattie EMatologiche dell'Adulto | Phase 2 |
| Recruiting | Selumetinib and Azacitidine in High Risk Chronic Blood Cancers NCT03326310 | University of Chicago | Phase 1 |
| Terminated | IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT NCT03696537 | Naoyuki G. Saito, M.D., Ph.D. | Phase 1 |
| Unknown | Iclusig PMS in CML or Ph+ALL Patients NCT03709017 | Korea Otsuka Pharmaceutical Co., Ltd. | — |
| Completed | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 NCT02890758 | Brenda Cooper, MD | Phase 1 |
| Unknown | The Hong Kong CML Registry NCT03625583 | The University of Hong Kong | — |
| Completed | Dynamic Changes in the Levels of sCD62L and SPARC in Chronic Myeloid Leukemia Patients During Imatinib Treatme NCT05387330 | Tanta University | — |
| Active Not Recruiting | Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression NCT03480360 | Dartmouth-Hitchcock Medical Center | Phase 3 |
| Unknown | CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies NCT04156256 | iCell Gene Therapeutics | EARLY_Phase 1 |
| Unknown | CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies NCT03795779 | iCell Gene Therapeutics | EARLY_Phase 1 |
| Recruiting | HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After NCT03326921 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Observational Study on CML Patients in Any Phase of the Disease Treated With Ponatinib (Iclusig®) NCT04048564 | Incyte BioSciences France | — |
| Unknown | Sleep Assessment in CML NCT03353558 | HaEmek Medical Center, Israel | — |
| Unknown | Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia NCT03228303 | Assiut University | EARLY_Phase 1 |
| Completed | Study of Chinese Newly Diagnosed Participants With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leuk NCT03509896 | Bristol-Myers Squibb | — |
| Completed | Effect of Pharmacogenetics on Imatinib Plasma Level and Response NCT03262974 | Assiut University | — |
| Unknown | Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia NCT03075969 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Unknown | The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous Leukaemia NCT03241199 | The University of Hong Kong | Phase 2 |
| Unknown | To Study the Impact of Stopping Therapy in Patients of CML With Molecular Remission NCT03062436 | Command Hospital, India | N/A |
| Unknown | KISS Study: Kinase Inhibition With Sprycel Start up NCT03193281 | University of Auckland, New Zealand | Phase 2 |
| Completed | Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphobla NCT03678454 | Incyte Biosciences Benelux | — |
| Completed | Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT NCT03018223 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Completed | Preparatory Work to Assess Adherence to Oral Chemotherapy NCT02895542 | Wake Forest University Health Sciences | — |
| Completed | Budget Impact Analysis of Discontinuing Tyrosin Kinase Inhibitors in Patients With Chronic Myeloid Leukemia Ac NCT03540654 | University Hospital, Bordeaux | — |
| Completed | Bosutinib in Elderly Chronic Myeloid Leukemia NCT02810990 | Gruppo Italiano Malattie EMatologiche dell'Adulto | Phase 2 |
| Terminated | Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Le NCT02709083 | Emory University | Phase 2 |
| Unknown | Vitro Study of Tigecycline to Treat Chronic Myeloid Leukemia NCT02883036 | Nanfang Hospital, Southern Medical University | — |
| Completed | Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery NCT02767388 | University of Nebraska | — |
| Active Not Recruiting | 2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients NCT02917720 | European LeukemiaNet | Phase 2 |
| Unknown | Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administr NCT02885766 | Fusion Pharma LLC | Phase 1 / Phase 2 |
| Completed | Nilotinib for Patients With Chronic Myeloid Leukemia in First Line and Any Subsequent Line NCT05734053 | Novartis Pharmaceuticals | — |
| Terminated | Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Im NCT02398825 | Gruppo Italiano Malattie EMatologiche dell'Adulto | Phase 2 |
| Withdrawn | Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders NCT02663648 | Shandong University | — |
| Completed | A Study of Dasatinib Management Among CP-CML (Chronic Phase, Chronic Myeloid Leukemia) Participants Initiating NCT04089839 | Bristol-Myers Squibb | — |
| Completed | Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Fir NCT02546674 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis NCT06042660 | Polish Adult Leukemia Group | — |
| Terminated | Retrospective Evaluation of CML Patients in the National Compassionate Program NCT02448095 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Completed | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malig NCT02556931 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Completed | Targeting Leukemic Stem Cell Expressing the IL-1RAP Protein in Chronic Myelogenous Leukemia (CML) NCT02842320 | Centre Hospitalier Universitaire de Besancon | N/A |
| Completed | Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy NCT02487069 | Nanfang Hospital, Southern Medical University | N/A |
| Unknown | Radotinib as 3rd or Later Line Therapy in CP-CML NCT02422719 | Ulsan University Hospital | Phase 2 |
| Completed | Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients NCT02253277 | Novartis Pharmaceuticals | Phase 1 |
| Unknown | Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chroni NCT02317159 | Cttq | Phase 4 |
| Completed | Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy NCT02353728 | Weill Medical College of Cornell University | Phase 2 |
| Completed | Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Tr NCT02129582 | Case Comprehensive Cancer Center | Phase 1 |
| Withdrawn | Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leu NCT02115672 | Sheba Medical Center | Phase 1 / Phase 2 |
| Terminated | A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients NCT02204722 | Dong-A ST Co., Ltd. | Phase 4 |
| Terminated | A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed D NCT02078960 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 1 / Phase 2 |
| Unknown | Treatment-free Remission Accomplished With Dasatinib in Patients With CML NCT02268370 | University Health Network, Toronto | Phase 2 |
| Unknown | LEONIDAS: Quality of Life Study in Chronic Myeloid Leukemia Patients NCT02164903 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Completed | Occupational Status and Hematological Disease NCT02057185 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Completed | Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients NCT02201459 | Hospices Civils de Lyon | Phase 3 |
| Unknown | Allogeneic SCT for CML, TKI Failure After TKI Failure NCT02172365 | University Health Network, Toronto | — |
| Terminated | An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 NCT02174445 | Prof. Dr. Nikolas von Bubnoff | Phase 3 |
| Completed | A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivo NCT02011945 | Bristol-Myers Squibb | Phase 1 |
| Completed | Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal NCT02103322 | Amneal Pharmaceuticals, LLC | Phase 2 / Phase 3 |
| Unknown | Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib NCT01761890 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Unknown | Regional Central Database Recording of Chronic Myeloid Leukemia NCT02869256 | Institut Bergonié | — |
| Unknown | Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Imm NCT02007811 | University of Erlangen-Nürnberg Medical School | Phase 1 / Phase 2 |
| Completed | Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity NCT02016833 | PX Biosolutions | — |
| Withdrawn | RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease. NCT01188889 | University of Michigan Rogel Cancer Center | Phase 1 / Phase 2 |
| Completed | Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously NCT01903733 | Pfizer | N/A |
| Unknown | Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors NCT01752062 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Completed | TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet Study NCT01860456 | University of Pisa | — |
| Completed | Follow-up of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leuke NCT02896829 | University Hospital, Bordeaux | — |
| Terminated | Nilotinib Plus Pegylated Interferon-α2b in CML NCT01866553 | Amsterdam UMC, location VUmc | Phase 2 |
| Unknown | Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase NCT01802450 | PETHEMA Foundation | Phase 2 |
| Completed | Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy NCT01819558 | Institut Paoli-Calmettes | Phase 1 / Phase 2 |
| Completed | Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop) NCT01698905 | Novartis Pharmaceuticals | Phase 2 |
| Terminated | Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylax NCT01749111 | Hospital Israelita Albert Einstein | Phase 3 |
| Completed | Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body NCT01795716 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Completed | TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER S NCT01657604 | University of Jena | Phase 3 |
| Completed | Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies NCT01606579 | Prism Pharma Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Pulmonary Vasculopathy Under Second-line Therapy of Chronic Myeloid Leukemia NCT01805843 | Medical University of Graz | — |
| Terminated | Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC) NCT01650805 | Ariad Pharmaceuticals | Phase 3 |
| Completed | European Stop Tyrosine Kinase Inhibitor Study NCT01596114 | European LeukemiaNet | Phase 3 |
| Completed | A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film- NCT01751919 | Dong-A ST Co., Ltd. | Phase 1 |
| Completed | Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning NCT01572662 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreate NCT01220648 | Novartis Pharmaceuticals | Phase 1 |
| Unknown | Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecul NCT01627132 | Shimousa Hematology Study Group | Phase 2 |
| Completed | Nilotinib in PH+, BCR-, ABL+ CML Patients NCT01535391 | Gruppo Italiano Malattie EMatologiche dell'Adulto | Phase 3 |
| Completed | Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients NCT01578213 | University of Milano Bicocca | Phase 4 |
| Unknown | Prospective Investigation of Dynamics of ABL Mutations in Imatinib Failed CML Patients Treated With Nilotinib NCT01562847 | Seoul St. Mary's Hospital | — |
| Terminated | Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients NCT01169753 | M.D. Anderson Cancer Center | N/A |
| Completed | Non-interventional Treatment Patterns Study in Chronic Phase Chronic Myelogenous Leukemia (CP-CML) NCT01394666 | Bristol-Myers Squibb | — |
| Completed | A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Ch NCT01077544 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients NCT01254188 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Phase I Study of OPB-51602 in Patients With Hematologic Malignancies NCT01344876 | Otsuka Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Da NCT01342679 | Kanto CML Study Group | Phase 2 |
| Completed | Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients NCT01275196 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia NCT01297543 | Cellerant Therapeutics | Phase 1 / Phase 2 |
| Recruiting | International Chronic Myeloid Leukemia Pediatric Study NCT01281735 | Poitiers University Hospital | — |
| Completed | Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting NCT01244750 | Bristol-Myers Squibb | — |
| Completed | Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza NCT01290302 | American Regent, Inc. | Phase 1 |
| Completed | Study to Evaluate the Pharmacokinetic Characteristics of Luckyvec 400mg Tablet, in Healthy Subjects NCT01270984 | Chong Kun Dang Pharmaceutical | Phase 1 |
| Completed | Patient Reported Outcomes in Chronic Myeloid Leukemia NCT01252589 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Completed | A Study Investigating the Predictive Value of Philadelphia Positive Stem Cell Properties in Newly Diagnosed Pa NCT01215487 | University of British Columbia | — |
| Completed | Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) NCT01207440 | Ariad Pharmaceuticals | Phase 2 |
| Completed | Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute L NCT01167166 | Traws Pharma, Inc. | Phase 1 / Phase 2 |
| Completed | Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor NCT01350245 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Unknown | Discontinuation Study of Imatinib in Adult CP CML Patients Who Have a Complete Molecular Response to Imatinib NCT01564836 | Seoul St. Mary's Hospital | N/A |
| Completed | To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in NCT01223898 | Novartis Pharmaceuticals | Phase 1 |
| Completed | A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation NCT01068301 | St. Jude Children's Research Hospital | Phase 1 |
| Completed | Mid-to Long-Term Outcomes in Chronic Myeloid Leukemia (CML) Patients With Complete Cytogenetic Response After NCT00896129 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Terminated | Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia NCT00895297 | European Society for Blood and Marrow Transplantation | Phase 2 |
| Completed | Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma NCT00965224 | Zwi Berneman | Phase 2 |
| Completed | Follow-up of Ph+ Chronic Myleoid Leukemia Patients in Complete Cytogenetic Response With Interferon Based Ther NCT01490853 | Università degli Studi di Brescia | — |
| Completed | Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies NCT00988013 | University of Illinois at Chicago | N/A |
| Terminated | T-cell Depleted Alternative Donor Transplantation NCT00968864 | Wake Forest University Health Sciences | Phase 2 |
| Completed | Investigating Intracellular and Plasma Imatinib Levels in Chronic Myeloid Leukemia NCT00947830 | Brian Leber | — |
| Completed | Nilotinib Pre and Post Allogeneic Stem Cell Transplantation NCT00750659 | Sheba Medical Center | Phase 2 |
| Terminated | Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treate NCT01073436 | University of Michigan Rogel Cancer Center | — |
| Completed | Allogeneic Stem Cell Transplantation for Children With CML NCT02707393 | St. Anna Kinderkrebsforschung | Phase 2 / Phase 3 |
| Terminated | Telemonitoring Study - for Chronic Myeloid Leukemia (CML) NCT01490983 | Rex Cancer Center, Raleigh, NC | N/A |
| Completed | Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leu NCT00852566 | Norwegian University of Science and Technology | Phase 2 |
| Completed | A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia NCT00866736 | Kanto CML Study Group | Phase 2 |
| Completed | Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation) NCT00827138 | Deciphera Pharmaceuticals, LLC | Phase 1 |
| Completed | A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Bla NCT01126892 | Novartis Pharmaceuticals | Phase 3 |
| Unknown | Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imati NCT01400074 | Seoul St. Mary's Hospital | Phase 3 |
| Completed | Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Th NCT00815321 | Singapore General Hospital | Phase 2 |
| Active Not Recruiting | CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene NCT00710892 | Baylor College of Medicine | Phase 1 |
| Terminated | Bendamustine in Acute Leukemia and MDS NCT00790855 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Impact of the Inhibitors of Tyrosine Kinase on the Male Fertility NCT01114087 | Assistance Publique - Hôpitaux de Paris | N/A |
| Approved For Marketing | Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Ac NCT00905593 | Novartis Pharmaceuticals | — |
| Completed | Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid NCT00786812 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who NCT00858806 | Università degli Studi di Brescia | Phase 2 |
| Completed | Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive NCT00574873 | Pfizer | Phase 3 |
| Withdrawn | Palifermin After Haploidentical PBSCT NCT00570999 | European Society for Blood and Marrow Transplantation | Phase 2 |
| Completed | Long Term Therapy With Imatinib: Development of Late Side Effects and Compliance to Treatment NCT00632255 | Imperial College London | — |
| Completed | Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Mye NCT00469729 | Gamida Cell -Teva Joint Venture Ltd. | Phase 2 / Phase 3 |
| Terminated | Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia NCT00573378 | University of Michigan Rogel Cancer Center | Phase 2 |
| Terminated | Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies NCT00593554 | Sherif S. Farag | Phase 2 |
| Completed | Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning Regimen For HLA Identical Sibling D NCT01683123 | Grupo Espanol de trasplantes hematopoyeticos y terapia celular | — |
| Completed | Nilotinib as First-line Treatment of Ph+ CML in Early Chronic Phase NCT00481052 | Gruppo Italiano Malattie EMatologiche dell'Adulto | Phase 2 |
| Terminated | Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic NCT00464113 | Exelixis | Phase 1 |
| Completed | Natural Killer Index From Hematopoietic Stem Cell Graft NCT00435864 | Nantes University Hospital | N/A |
| Completed | Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML NCT00462943 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 2 |
| Withdrawn | Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadel NCT00349518 | Bristol-Myers Squibb | Phase 2 / Phase 3 |
| Withdrawn | Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia NCT00162513 | Hadassah Medical Organization | Phase 1 / Phase 2 |
| Completed | Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With th NCT00375219 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 2 |
| Terminated | Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias NCT00522990 | Astex Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Completed | Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia NCT00469014 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematolog NCT00460694 | Singapore General Hospital | Phase 1 / Phase 2 |
| Completed | Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia NCT00352677 | CytRx | Phase 1 |
| Completed | Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias NCT00261846 | Pfizer | Phase 2 |
| No Longer Available | Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leuk NCT00302016 | Novartis Pharmaceuticals | — |
| Completed | Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease NCT00267085 | M.D. Anderson Cancer Center | Phase 2 |
| Unknown | Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation NCT00328237 | Colorado Blood Cancer Institute | Phase 2 |
| Completed | Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients NCT00493181 | M.D. Anderson Cancer Center | Phase 2 |
| Unknown | Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haemat NCT00598624 | IRCCS San Raffaele | Phase 2 |
| Completed | Use of SV40 Vectors to Treat Chronic Myeloid Leukemia (CML) NCT00257647 | Hadassah Medical Organization | — |
| Completed | Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies NCT00143559 | St. Jude Children's Research Hospital | Phase 2 |
| Completed | Prophylactic Transfer of Leukemia-reactive T Cells After Allogeneic Transplantation NCT00460629 | University Hospital Carl Gustav Carus | Phase 1 / Phase 2 |
| Completed | Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant NCT00354120 | Gruppo Italiano Trapianto di Midollo Osseo | Phase 2 / Phase 3 |
| Completed | Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia NCT00103844 | Bristol-Myers Squibb | Phase 2 |
| Completed | Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolera NCT00101660 | Bristol-Myers Squibb | Phase 2 |
| Terminated | Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib NCT00461929 | University Health Network, Toronto | Phase 4 |
| Completed | Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromoso NCT00101595 | Bristol-Myers Squibb | Phase 2 |
| Completed | Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intoleran NCT00101816 | Bristol-Myers Squibb | Phase 2 |
| Completed | Glivec in Pediatric Chronic Myeloid Leukemia (CML) NCT00845221 | Poitiers University Hospital | Phase 4 |
| Completed | Imatinib Standard Dose (400 mg/Day) Versus Imatinib High Dose (800 mg/Day) NCT00514488 | University of Bologna | Phase 3 |
| Completed | HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With NCT00145626 | St. Jude Children's Research Hospital | Phase 2 |
| Unknown | AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Res NCT00146913 | Hospices Civils de Lyon | Phase 2 |
| Unknown | Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML NCT00327262 | Central European Leukemia Study Group | Phase 3 |
| Completed | Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) NCT00067028 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | STI571 ProspectIve RandomIzed Trial: SPIRIT NCT00219739 | Poitiers University Hospital | Phase 3 |
| Completed | Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies NCT00145613 | St. Jude Children's Research Hospital | Phase 2 |
| Completed | Experimental Bone Marrow Transplant Protocol NCT00061581 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Terminated | Reduced Intensity AlloSCT in(CML) With Persistent Disease NCT00531310 | Columbia University | Phase 2 |
| Completed | Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorde NCT00516152 | University of California, San Francisco | Phase 2 |
| Completed | Stem Cell Transplantation for Patients With Hematologic Malignancies NCT00152139 | St. Jude Children's Research Hospital | Phase 3 |
| Completed | Safety and Efficacy of Imatinib in Chronic Myelogenous Patients Older Than 70 Years NCT00219752 | Poitiers University Hospital | Phase 2 |
| Completed | Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation NCT00219726 | Poitiers University Hospital | Phase 2 |
| Completed | Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematolo NCT00513175 | University of California, San Francisco | — |
| Completed | Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and NCT00038675 | M.D. Anderson Cancer Center | N/A |
| Terminated | Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous NCT00219765 | Poitiers University Hospital | Phase 1 / Phase 2 |
| Terminated | Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon NCT00511121 | University of Bologna | Phase 2 |
| Completed | Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia NCT00511303 | University of Bologna | Phase 2 |
| Completed | Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia in Acce NCT00514969 | University of Bologna | Phase 2 |
| Completed | PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML NCT00303290 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Modified Bone Marrow Stem Cell Transplantation for Chronic Myelogenous Leukemia NCT00001144 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Completed | The Collection of Peripheral Blood Lymphocytes and Marrow Progenitor Cells From Normal Volunteers and Voluntee NCT00001432 | National Cancer Institute (NCI) | — |
| Available | The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder NCT00854841 | Pusan National University Hospital | — |
| No Longer Available | Compassionate Use Ponatinib NCT01549548 | OHSU Knight Cancer Institute | — |
| No Longer Available | Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Trans NCT01200017 | Christopher Dvorak | — |
| No Longer Available | Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation NCT02258490 | Emory University | — |